Switch theme
Sign up to access all valuation multiples
Wuhan Keqian Biology Co Ltd is engaged in research and development, production, sales and animal epidemic prevention technical services of veterinary biological products. The company's products include Combination plan; Vaccine for swine; Poultry vaccine; Pet vaccine; and Diagnostic reagent.
2001
n/a
LTM Revenue $147M
LTM EBITDA $69.9M
$891M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Keqian Biology has a last 12-month revenue of $147M and a last 12-month EBITDA of $69.9M.
In the most recent fiscal year, Keqian Biology achieved revenue of $147M and an EBITDA of $79.9M.
Keqian Biology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Keqian Biology valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $147M | $139M | XXX | XXX | XXX |
| Gross Profit | $121M | $102M | XXX | XXX | XXX |
| Gross Margin | 83% | 73% | XXX | XXX | XXX |
| EBITDA | $79.9M | $68.2M | XXX | XXX | XXX |
| EBITDA Margin | 55% | 49% | XXX | XXX | XXX |
| Net Profit | $78.6M | $56.4M | XXX | XXX | XXX |
| Net Margin | 54% | 41% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Keqian Biology 's stock price is CNY 16 (or $2).
Keqian Biology has current market cap of CNY 7.5B (or $1.0B), and EV of CNY 6.5B (or $891M).
See Keqian Biology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $891M | $1.0B | XXX | XXX | XXX | XXX | $0.11 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Keqian Biology has market cap of $1.0B and EV of $891M.
Keqian Biology 's trades at 6.1x LTM EV/Revenue multiple, and 12.7x LTM EBITDA.
Analysts estimate Keqian Biology 's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Keqian Biology and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $891M | XXX | XXX | XXX |
| EV/Revenue | 6.4x | XXX | XXX | XXX |
| EV/EBITDA | 13.1x | XXX | XXX | XXX |
| P/E | 20.6x | XXX | XXX | XXX |
| P/E/Growth | 0.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpKeqian Biology 's NTM/LTM revenue growth is 22%
Keqian Biology 's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Keqian Biology 's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Keqian Biology 's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Keqian Biology and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -5% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 49% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -15% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 71% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 27% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Keqian Biology acquired XXX companies to date.
Last acquisition by Keqian Biology was XXXXXXXX, XXXXX XXXXX XXXXXX . Keqian Biology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Keqian Biology founded? | Keqian Biology was founded in 2001. |
| Where is Keqian Biology headquartered? | Keqian Biology is headquartered in China. |
| Is Keqian Biology publicy listed? | Yes, Keqian Biology is a public company listed on SHG. |
| What is the stock symbol of Keqian Biology ? | Keqian Biology trades under 688526 ticker. |
| When did Keqian Biology go public? | Keqian Biology went public in 2020. |
| Who are competitors of Keqian Biology ? | Similar companies to Keqian Biology include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Keqian Biology ? | Keqian Biology 's current market cap is $1.0B |
| What is the current revenue of Keqian Biology ? | Keqian Biology 's last 12-month revenue is $147M. |
| What is the current EBITDA of Keqian Biology ? | Keqian Biology 's last 12-month EBITDA is $69.9M. |
| What is the current EV/Revenue multiple of Keqian Biology ? | Current revenue multiple of Keqian Biology is 6.1x. |
| What is the current EV/EBITDA multiple of Keqian Biology ? | Current EBITDA multiple of Keqian Biology is 12.7x. |
| What is the current revenue growth of Keqian Biology ? | Keqian Biology revenue growth between 2023 and 2024 was -5%. |
| Is Keqian Biology profitable? | Yes, Keqian Biology is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
